SG150550A1 - Pharmaceutical preparation containing an antibody for the egf receptor - Google Patents

Pharmaceutical preparation containing an antibody for the egf receptor

Info

Publication number: SG150550A1
Authority: SG; Singapore
Prior art keywords: antibody; pharmaceutical preparation; egf receptor; preparation containing; receptor
Prior art date: 2003-11-26

Application number

SG200901382-2A

Other languages

English (en)

Inventor

Hanns-Christian Mahler

Robert Mueller

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-26

Filing date

2004-10-26

Publication date

2009-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34609304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG150550(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-26 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2009-03-30 Publication of SG150550A1 publication Critical patent/SG150550A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Inorganic Chemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG200901382-2A 2003-11-26 2004-10-26 Pharmaceutical preparation containing an antibody for the egf receptor SG150550A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10355251A DE10355251A1 (de)	2003-11-26	2003-11-26	Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor

Publications (1)

Publication Number	Publication Date
SG150550A1 true SG150550A1 (en)	2009-03-30

Family

ID=34609304

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200901382-2A SG150550A1 (en)	2003-11-26	2004-10-26	Pharmaceutical preparation containing an antibody for the egf receptor

Country Status (30)

Country	Link
US (2)	US20050175611A1 (fr)
EP (1)	EP1687031B1 (fr)
JP (1)	JP2007512266A (fr)
KR (1)	KR20060110305A (fr)
CN (1)	CN1886158B (fr)
AR (1)	AR047949A1 (fr)
AT (1)	ATE457740T1 (fr)
AU (1)	AU2004298728B2 (fr)
BR (1)	BRPI0416986A (fr)
CA (1)	CA2547060A1 (fr)
CO (1)	CO5690620A2 (fr)
CY (1)	CY1110344T1 (fr)
DE (2)	DE10355251A1 (fr)
DK (1)	DK1687031T3 (fr)
EC (1)	ECSP066662A (fr)
ES (1)	ES2339671T3 (fr)
IL (1)	IL175727A0 (fr)
MX (1)	MXPA06005901A (fr)
MY (1)	MY145214A (fr)
NZ (1)	NZ548129A (fr)
PE (1)	PE20050586A1 (fr)
PL (1)	PL1687031T3 (fr)
PT (1)	PT1687031E (fr)
RU (1)	RU2381036C2 (fr)
SG (1)	SG150550A1 (fr)
SI (1)	SI1687031T1 (fr)
TW (1)	TWI322693B (fr)
UA (1)	UA90460C2 (fr)
WO (1)	WO2005058365A1 (fr)
ZA (1)	ZA200605219B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212004B2 (en) *	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6812327B1 (en) *	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
MXPA02012434A (es) *	2000-06-16	2004-09-06	Cambridge Antibody Tech	Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US9168286B2 (en) *	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) *	2005-10-13	2013-05-02	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP3219328B1 (fr)	2005-12-29	2020-06-17	Janssen Biotech, Inc.	Compositions, procédés et utilisations d'anticorps humains anti-il-23
US8211649B2 (en) *	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
CN101426817B (zh)	2006-04-21	2013-07-10	诺华有限公司	拮抗性抗-cd40抗体药物组合物
WO2008051363A2 (fr) *	2006-10-20	2008-05-02	Amgen Inc.	Formulations stables de polypeptide
WO2008079818A2 (fr) *	2006-12-21	2008-07-03	Soluprin Pharmaceuticals, Inc.	Administration intraveineuse de formulations analgésiques hydrosolubles
EP2205276A4 (fr) *	2007-09-28	2012-08-15	Janssen Biotech Inc	Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations
KR20090056543A (ko) *	2007-11-30	2009-06-03	주식회사 녹십자	Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
CN101716343A (zh) *	2008-10-09	2010-06-02	哈药集团生物工程有限公司	一种单克隆抗体的冻干制剂
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN101797383A (zh) *	2009-02-05	2010-08-11	哈药集团生物工程有限公司	一种单克隆抗体的水针制剂
US20110014190A1 (en) *	2009-02-12	2011-01-20	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CA2760185A1 (fr) *	2009-05-04	2010-11-11	Abbott Biotechnology Ltd.	Formulations stables a concentration proteique elevee d'anticorps anti-tnf-alpha humain
EP2519262A2 (fr) *	2009-12-29	2012-11-07	F. Hoffmann-La Roche AG	Nouvelle formation d'anticorps
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US20120294866A1 (en) *	2010-01-19	2012-11-22	F. Hoffmann-La Roche Ag	Pharmaceutical formulation for proteins
MX347602B (es)	2011-01-28	2017-05-03	Sanofi Biotechnology	Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MX2013014615A (es) *	2011-06-16	2014-02-17	Dsm Ip Assets Bv	Purificacion de anticuerpos por cromatografia de unidad unica.
AR087305A1 (es)	2011-07-28	2014-03-12	Regeneron Pharma	Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh)	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
SG10201604104PA (en)	2011-10-25	2016-07-28	Prothena Therapeutics Ltd	Antibody formulations and methods
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
EP2890782A1 (fr)	2012-09-02	2015-07-08	AbbVie Inc.	Procédés de contrôle de l'hétérogénéité des protéines
EP2919804B1 (fr)	2012-11-13	2018-01-31	Adocia	Formulation à action rapide d'insuline comprenant un composé anionique substitué
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (fr)	2013-03-14	2014-09-25	Abbvie Inc.	Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
WO2014159579A1 (fr)	2013-03-14	2014-10-02	Abbvie Inc.	Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
FR3020947B1 (fr) *	2014-05-14	2018-08-31	Adocia	Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en)	2014-05-14	2017-10-24	Adocia	Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR101776879B1 (ko)	2015-01-19	2017-09-08	주식회사 녹십자	항-egfr 항체를 포함하는 약학 제제
US10772956B2 (en)	2015-08-18	2020-09-15	Regeneron Pharmaceuticals, Inc.	Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
FR3043557B1 (fr)	2015-11-16	2019-05-31	Adocia	Composition a action rapide d'insuline comprenant un citrate substitue
CN107773755B (zh) *	2016-08-31	2021-06-22	上海津曼特生物科技有限公司	抗表皮生长因子受体单克隆抗体的注射液制剂
US20190269757A1 (en)	2018-03-05	2019-09-05	Janssen Biotech, Inc.	Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20210322554A1 (en) *	2018-09-10	2021-10-21	Dow Global Technologies Llc	A composition comprising a protein and a polyalkoxy fatty acyl surfactant
CN110960490A (zh) *	2018-09-28	2020-04-07	江苏恒瑞医药股份有限公司	一种抗egfr抗体偶联药物组合物及其用途
AU2019383017A1 (en)	2018-11-20	2021-06-03	Janssen Biotech, Inc.	Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
EP3888678A4 (fr) *	2018-11-29	2022-02-16	Harbour Biomed Therapeutics Limited	Préparation d'un anticorps anti-pd-l1
EP3917618A1 (fr)	2019-01-31	2021-12-08	Sanofi Biotechnology	Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
JP2022545312A (ja)	2019-04-24	2022-10-27	サノフィ・バイオテクノロジー	関節リウマチの診断及び処置の方法
KR20220012883A (ko)	2019-05-23	2022-02-04	얀센 바이오테크 인코포레이티드	Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
MA56116A (fr)	2019-06-04	2022-04-13	Stefano Fiore	Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde
BR112022023489A2 (pt)	2020-05-21	2023-03-14	Janssen Biotech Inc	Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2022230390A1 (fr) *	2021-04-27	2022-11-03	国立研究開発法人量子科学技術研究開発機構	Procédé de stockage d'intermédiaire pour composition radiopharmaceutique, procédé de préparation ou de stockage de composition radiopharmaceutique, composition intermédiaire pour composition radiopharmaceutique, et formulation pharmaceutique
CN115300623B (zh) *	2021-05-08	2024-06-21	盛禾(中国)生物制药有限公司	抗egfr融合蛋白或其抗原结合片段的组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277828B1 (en) *	1993-08-20	2001-08-21	Syntex (U.S.A.) Inc.	Pharmaceutical formulations of nerve growth factor
SI1516628T1 (sl) *	1995-07-27	2013-10-30	Genentech, Inc.	Stabilna izotonična liofilizirana proteinska formulacija
EP0852951A1 (fr) *	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
JP4731793B2 (ja) *	2000-12-28	2011-07-27	アルセアテクノロジーズインコーポレイテッド	抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
DE10133394A1 (de) *	2001-07-13	2003-01-30	Merck Patent Gmbh	Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) *	2001-12-21	2003-07-03	Merck Patent Gmbh	Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
WO2004060343A1 (fr) *	2002-12-31	2004-07-22	Nektar Therapeutics	Particules contenant des anticorps et compositions

2003
- 2003-11-26 DE DE10355251A patent/DE10355251A1/de not_active Withdrawn
2004
- 2004-10-26 WO PCT/EP2004/012044 patent/WO2005058365A1/fr not_active Ceased
- 2004-10-26 ES ES04820387T patent/ES2339671T3/es not_active Expired - Lifetime
- 2004-10-26 SI SI200431369T patent/SI1687031T1/sl unknown
- 2004-10-26 PL PL04820387T patent/PL1687031T3/pl unknown
- 2004-10-26 BR BRPI0416986-7A patent/BRPI0416986A/pt not_active IP Right Cessation
- 2004-10-26 EP EP04820387A patent/EP1687031B1/fr not_active Revoked
- 2004-10-26 DK DK04820387.1T patent/DK1687031T3/da active
- 2004-10-26 CA CA002547060A patent/CA2547060A1/fr not_active Abandoned
- 2004-10-26 CN CN2004800347064A patent/CN1886158B/zh not_active Expired - Fee Related
- 2004-10-26 RU RU2006122638/15A patent/RU2381036C2/ru not_active IP Right Cessation
- 2004-10-26 JP JP2006540214A patent/JP2007512266A/ja active Pending
- 2004-10-26 MX MXPA06005901A patent/MXPA06005901A/es active IP Right Grant
- 2004-10-26 NZ NZ548129A patent/NZ548129A/en not_active IP Right Cessation
- 2004-10-26 AT AT04820387T patent/ATE457740T1/de active
- 2004-10-26 KR KR1020067010225A patent/KR20060110305A/ko not_active Ceased
- 2004-10-26 DE DE502004010783T patent/DE502004010783D1/de not_active Expired - Lifetime
- 2004-10-26 UA UAA200607106A patent/UA90460C2/ru unknown
- 2004-10-26 SG SG200901382-2A patent/SG150550A1/en unknown
- 2004-10-26 AU AU2004298728A patent/AU2004298728B2/en not_active Ceased
- 2004-10-26 PT PT04820387T patent/PT1687031E/pt unknown
- 2004-11-22 MY MYPI20044833A patent/MY145214A/en unknown
- 2004-11-24 PE PE2004001152A patent/PE20050586A1/es not_active Application Discontinuation
- 2004-11-25 TW TW093136361A patent/TWI322693B/zh not_active IP Right Cessation
- 2004-11-26 AR ARP040104380A patent/AR047949A1/es not_active Application Discontinuation
- 2004-11-26 US US10/996,597 patent/US20050175611A1/en not_active Abandoned
2006
- 2006-05-17 IL IL175727A patent/IL175727A0/en unknown
- 2006-05-24 CO CO06050041A patent/CO5690620A2/es not_active Application Discontinuation
- 2006-06-21 EC EC2006006662A patent/ECSP066662A/es unknown
- 2006-06-23 ZA ZA200605219A patent/ZA200605219B/en unknown
2010
- 2010-05-13 CY CY20101100415T patent/CY1110344T1/el unknown
2011
- 2011-03-24 US US13/070,952 patent/US20110177068A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PE20050586A1 (es)	2005-08-15
US20110177068A1 (en)	2011-07-21
AU2004298728B2 (en)	2010-09-16
CN1886158A (zh)	2006-12-27
CY1110344T1 (el)	2015-01-14
EP1687031B1 (fr)	2010-02-17
KR20060110305A (ko)	2006-10-24
AU2004298728A1 (en)	2005-06-30
DK1687031T3 (da)	2010-05-31
HK1095534A1 (en)	2007-05-11
ATE457740T1 (de)	2010-03-15
DE10355251A1 (de)	2005-06-23
ES2339671T3 (es)	2010-05-24
ECSP066662A (es)	2006-10-25
IL175727A0 (en)	2006-09-05
PT1687031E (pt)	2010-05-21
DE502004010783D1 (de)	2010-04-01
PL1687031T3 (pl)	2010-06-30
TW200531702A (en)	2005-10-01
BRPI0416986A (pt)	2007-02-06
RU2381036C2 (ru)	2010-02-10
SI1687031T1 (sl)	2010-04-30
ZA200605219B (en)	2007-04-25
NZ548129A (en)	2010-09-30
MXPA06005901A (es)	2006-06-27
CO5690620A2 (es)	2006-10-31
CA2547060A1 (fr)	2005-06-30
WO2005058365A1 (fr)	2005-06-30
EP1687031A1 (fr)	2006-08-09
JP2007512266A (ja)	2007-05-17
CN1886158B (zh)	2011-09-07
UA90460C2 (ru)	2010-05-11
RU2006122638A (ru)	2008-01-10
US20050175611A1 (en)	2005-08-11
MY145214A (en)	2012-01-13
AR047949A1 (es)	2006-03-15
TWI322693B (en)	2010-04-01

Publication	Publication Date	Title
SG150550A1 (en)	2009-03-30	Pharmaceutical preparation containing an antibody for the egf receptor
MY139055A (en)	2009-08-28	Lyophilised preparation containing antibodies to the egf receptor
IL273422A (en)	2020-05-31	Methods and systems for extracorporeal organ treatment
MY142777A (en)	2010-12-31	Substituted indole-o-glucosides
UA87991C2 (en)	2009-09-10	Substituted indole-o-glucosides
MXPA03010134A (es)	2004-03-10	Derivados de ciclohexan-1-4-diamina sustituidos.
GEP20094845B (en)	2009-11-25	Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MY136764A (en)	2008-11-28	Indole-3-carboxamides as glucokinase (gk) activators
MY137181A (en)	2009-01-30	Pulmonary administration of chemically modified insulin
IL190796A (en)	2013-04-30	Composition containing nucleic acid encoded by anti-osteoclastogenic protein
IL195338A0 (en)	2011-08-01	Optimized fc variants and methods for their generation
DK1349856T3 (da)	2005-10-17	Isoindolin-1-on-glucokinase-aktivatorer
ZA200606620B (en)	2008-02-27	Methods of modulating IL-23 activity ; related reagents
BR0208741A (pt)	2004-06-22	Derivados de piperidina
TW200624426A (en)	2006-07-16	BACE inhibitors
DE602004017326D1 (de)	2008-12-04	Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
IN2012DN03844A (fr)	2015-08-28
TW200503619A (en)	2005-02-01	Use of isoindolinone derivatives as insecticides
UA106200C2 (uk)	2014-08-11	Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
DK1411971T3 (da)	2006-08-07	Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet
IL189286A0 (en)	2008-06-05	Novel cysteine protease inhibitors and their therapeutic applications
TW200510323A (en)	2005-03-16	Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
EA200200853A1 (ru)	2003-02-27	Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
WO2002024181A3 (fr)	2003-04-17	Utilisation de la melatonine pour induire une anesthesie generale
MXPA04000272A (es)	2004-05-04	Derivados de 4-aminociclohexanol sustituidos.